ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) — Market Cap & Net Worth
Market Cap & Net Worth: ACADIA Pharmaceuticals Inc (ACAD)
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) has a market capitalization of $3.66 Billion ($3.66 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4284 globally and #1484 in its home market, demonstrating a 4.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACADIA Pharmaceuticals Inc's stock price $25.87 by its total outstanding shares 171235870 (171.24 Million). See ACAD capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
ACADIA Pharmaceuticals Inc Market Cap History: 2015 to 2026
ACADIA Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $6.10 Billion to $4.43 Billion (-2.49% CAGR).
Index Memberships
ACADIA Pharmaceuticals Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$935.64 Billion | 0.39% | #26 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.09 Trillion | 0.34% | #18 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.15% | #103 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #495 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.21% | #66 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.60 Trillion | 0.15% | #137 of 602 |
Weight: ACADIA Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ACADIA Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACADIA Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.27x
ACADIA Pharmaceuticals Inc's market cap is 4.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.70x
ACADIA Pharmaceuticals Inc's market cap is 11.70 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.94 Billion | $17.33 Million | -$271.39 Million | 284.95x | N/A |
| 2017 | $5.16 Billion | $124.90 Million | -$289.40 Million | 41.28x | N/A |
| 2018 | $2.77 Billion | $223.81 Million | -$245.19 Million | 12.37x | N/A |
| 2019 | $7.33 Billion | $339.08 Million | -$235.26 Million | 21.60x | N/A |
| 2020 | $9.15 Billion | $441.75 Million | -$281.58 Million | 20.72x | N/A |
| 2021 | $4.00 Billion | $484.14 Million | -$167.87 Million | 8.26x | N/A |
| 2022 | $2.73 Billion | $517.24 Million | -$215.97 Million | 5.27x | N/A |
| 2023 | $5.36 Billion | $726.44 Million | -$61.29 Million | 7.38x | N/A |
| 2024 | $3.14 Billion | $957.80 Million | $226.45 Million | 3.28x | 13.88x |
| 2025 | $4.57 Billion | $1.07 Billion | $391.00 Million | 4.27x | 11.70x |
Competitor Companies of ACAD by Market Capitalization
Companies near ACADIA Pharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to ACADIA Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
ACADIA Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ACADIA Pharmaceuticals Inc's market cap moved from $6.10 Billion to $ 4.43 Billion, with a yearly change of -2.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.43 Billion | -3.14% |
| 2025 | $4.57 Billion | +45.56% |
| 2024 | $3.14 Billion | -41.39% |
| 2023 | $5.36 Billion | +96.67% |
| 2022 | $2.73 Billion | -31.79% |
| 2021 | $4.00 Billion | -56.34% |
| 2020 | $9.15 Billion | +24.96% |
| 2019 | $7.33 Billion | +164.56% |
| 2018 | $2.77 Billion | -46.30% |
| 2017 | $5.16 Billion | +4.40% |
| 2016 | $4.94 Billion | -19.10% |
| 2015 | $6.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of ACADIA Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.66 Billion USD |
| MoneyControl | $3.66 Billion USD |
| MarketWatch | $3.66 Billion USD |
| marketcap.company | $3.66 Billion USD |
| Reuters | $3.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more